| |
|
|
Cenix BioScience conducts contract research and technology development focused on cell-based and in vivo applications of RNA interference (RNAi), miRNA modulation and high content phenotyping to accelerate the discovery and validation of novel therapeutic drug targets and the pre-clinical development of new drug candidates.
With roots as a pioneer of genome-scale RNAi screening and long-standing contributions towards refining best practices in this field, Cenix has built-up leading scientific, technical and commercial track records, successfully advancing therapeutic programs for numerous major industry and academic partners in a wide range of disease areas.
Our proven approach, as a mature and thoroughly-tested industrial research partner, focuses on fully customized, multi-staged projects reflecting 12 years of constantly perfected design, planning, implementation and reporting to offer our partners maximal strategic value with carefully minimized risk and full data transparency.
|
